NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 18 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Numa Numa Resources Inc. Eyes Mining Opportunities as Bougainville Charts Its Future
Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements. Numa Numa Resources is supporting…
-
QualityStocksNewsBreaks – Market Street Capital Inc. Highlights Importance of Exit Readiness for Founders
Market Street Capital emphasizes that founders of privately held, middle-market businesses should begin preparing for an…
-
From Tokenization to Production: MindWave Innovations Inc. (NYSE American: APUS) Positions MindChain for the Next Phase of Real-World Assets
Real-world asset activity is moving beyond proof-of-concept deployments, with tokenized funds, Treasuries, private credit and…